UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy

Annals of oncology, 2010-05, Vol.21 (5), p.1083-1088

2010

Volltextzugriff (PDF)

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Annals of oncology, 2017-11, Vol.28 (11), p.2820-2826

2017

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin

Annals of oncology, 2017-10, Vol.28 (10), p.2547-2551

2017

Volltextzugriff (PDF)

Cancer–testis antigen expression in triple-negative breast cancer

Annals of oncology, 2011-01, Vol.22 (1), p.98-103

2011

Volltextzugriff (PDF)

Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer

Breast cancer research and treatment, 2012-07, Vol.134 (1), p.277-282

2012

Volltextzugriff (PDF)

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects

Annals of oncology, 2006-02, Vol.17 (2), p.232-238

2006

Volltextzugriff (PDF)

A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma

British journal of cancer, 2009-01, Vol.100 (1), p.28-36

2009

Volltextzugriff (PDF)

Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?

Clinical & translational oncology, 2021-08, Vol.23 (8), p.1717-1726

2021

Volltextzugriff (PDF)

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

ESMO open, 2021-06, Vol.6 (3), p.100118-100118, Article 100118

2021

Volltextzugriff (PDF)

Very young women (<35 years) with operable breast cancer: features of disease at presentation

Annals of oncology, 2002-02, Vol.13 (2), p.273-279

2002

Volltextzugriff (PDF)

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99

Annals of oncology, 2017-02, Vol.28 (2), p.305-312

2017

Volltextzugriff (PDF)

Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial

Annals of oncology, 2017-09, Vol.28 (9), p.2206-2212

2017

Volltextzugriff (PDF)

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

Annals of oncology, 2002, Vol.13 (1), p.73-80

2002

Volltextzugriff (PDF)

Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology

Medical Oncology, 2017-05, Vol.34 (5), p.86, Article 86

2017

Volltextzugriff (PDF)

Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer

Annals of oncology, 2006-10, Vol.17 (10), p.1512-1516

2006

Volltextzugriff (PDF)

Should liver metastases of breast cancer be biopsied to improve treatment choice?

Annals of oncology, 2011-10, Vol.22 (10), p.2227-2233

2011

Volltextzugriff (PDF)

Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors

Annals of oncology, 2007-02, Vol.18 (2), p.288-292

2007

Volltextzugriff (PDF)

Sunitinib 2 weeks on, 1 off: strengths and weaknesses

Annals of oncology, 2015-07, Vol.26 (7), p.1511-1512

2015

Volltextzugriff (PDF)

Activity of fulvestrant in HER2-overexpressing advanced breast cancer

Annals of oncology, 2010-06, Vol.21 (6), p.1246-1253

2010

Volltextzugriff (PDF)

Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications

Annals of oncology, 2008-05, Vol.19 (5), p.891-897

2008

Volltextzugriff (PDF)

Jaw avascular bone necrosis associated with long-term use of biphosphonates

Annals of oncology, 2005-07, Vol.16 (7), p.1207-1208

2005

Volltextzugriff (PDF)

Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer

Annals of oncology, 2006-02, Vol.17 (2), p.322-329

2006

Volltextzugriff (PDF)

Totally implantable central venous access ports for long-term chemotherapy : A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days

Annals of oncology, 1998-07, Vol.9 (7), p.767-773

1998

Volltextzugriff (PDF)

High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel

Annals of oncology, 2001-03, Vol.12 (3), p.353-356

2001

Volltextzugriff (PDF)

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)

Annals of oncology, 2007-01, Vol.18 (1), p.64-69

2007

Volltextzugriff (PDF)

1 – 25 von 251

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(238)
Mit Volltextzugriff
(224)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(124)
Life Sciences & Biomedicine
(115)
Humans
(89)
Oncology
(88)
Female
(72)
Middle Aged
(72)
Aged
(64)
Biological And Medical Sciences
(59)
Adult
(57)
Medical Sciences
(54)
Pharmacology. Drug Treatments
(41)
Antineoplastic Agents
(40)
Male
(37)
Breast Neoplasms - Drug Therapy
(36)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(34)
Breast Neoplasms - Pathology
(31)
Breast Cancer
(29)
Chemotherapy
(29)
Tumors
(29)
Gynecology. Andrology. Obstetrics
(22)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin

Cancer–testis antigen expression in triple-negative breast cancer

Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects

A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma

Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

Very young women (<35 years) with operable breast cancer: features of disease at presentation

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99

Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology

Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer

Should liver metastases of breast cancer be biopsied to improve treatment choice?

Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors

Sunitinib 2 weeks on, 1 off: strengths and weaknesses

Activity of fulvestrant in HER2-overexpressing advanced breast cancer

Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications

Jaw avascular bone necrosis associated with long-term use of biphosphonates

Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer

Totally implantable central venous access ports for long-term chemotherapy : A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days

High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)

Suchergebnisse filtern